Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae218 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Laura H Rosenberger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States. Hauptthemen laut MEDLINE: Phyllodes Tumor, Breast Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Malignant phyllodes tumors (MPT) are rare fibroepithelial breast cancers with no known effective systemic therapy; metastatic progression portends a dismal prognosis. We sought to describe the genomic landscape of MPTs through genomic profiling and immunotherapeutic biomarker analysis. Materials and methods Cases of sequenced MPT were identified from a Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited laboratory (Foundation Medicine). All cases underwent genomic profiling using adaptor ligation-based, next-generation sequencing assay of 324 genes. Tumor agnostic immunotherapy biomarkers, microsatellite instability, tumor mutational burden (TMB), and programmed death-ligand 1 (PD-L1) expression were evaluated. Fisher’s Exact Tests and analysis of variance were used to test for differences between groups and for continuous variables as appropriate.
Results
Of 135 MPT cases identified; 94 (69.6%) were localized/locally recurrent and 41 (30.4%) were metastatic. Median age was 54 years (range 14-86). The median TMB was 2.5 mut/Mb and 3 were TMB-high (≥10 mut/Mb). 21.4% were PD-L1+ via Dako 22C3 assay (CPS ≥1). Most commonly altered genes included TERT-promoter (69.7%), CDKN2A (45.9%), TP53 (37.8%), NF1 (35.6%), CDKN2B (33.3%), MED12 (28.9%), MTAP (27.7%), KMT2D (22.2%), PIK3CA (20.0%), PTEN (18.5%), and RB1 (18.5%). Several tumors harboring genomic alterations with US Food and Drug Administration-approved indications in other tumor types were found including NF1, PIK3CA, EGFR Exon 19/20 insertions, and BRAF V600E mutations.
Conclusions
In the largest genomic evaluation of MPT to date, multiple clinically actionable mutations were found. Routine sequencing of metastatic MPT may provide additional information to guide treatment decisions and clinical trial enrollment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States.
- Duke Cancer Institute, Duke University, Durham, NC 27710, United States.
- Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
- Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
- Foundation Medicine, Inc., Cambridge, MA 02141, United States.
- Department of Pathology, Urology, and Oncology, Upstate Medical University, Syracuse, NY 13210, United States.
ORCID-Profile: Laura H Rosenberger, Richard F Riedel
Zitieren
APA
Rosenberger, L. H., Riedel, R. F., Diego, E. J., Nash, A. L., Grilley-Olson, J. E., Danziger, N. A., Sokol, E. S., Ross, J. S., & Sammons, S. L. (2024). Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities. The Oncologist. https://doi.org/10.1093/oncolo/oyae218
Vancouver
Rosenberger LH, Riedel RF, Diego EJ, Nash AL, Grilley-Olson JE, Danziger NA, et al. Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities. The Oncologist. 2024. doi:10.1093/oncolo/oyae218
BibTeX
@article{Rosenberger2024,
author = {Rosenberger, Laura H and Riedel, Richard F and Diego, Emilia J and Nash, Amanda L and Grilley-Olson, Juneko E and Danziger, Natalie A and Sokol, Ethan S and Ross, Jeffrey S and Sammons, Sarah L},
title = {Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae218}
}
EUVIMED